Travoprost Ophthalmic Solution shortage
To Be Discontinued 2 presentations · 1 manufacturers · first FDA posting 2026-07-07 · last update 2026-07-07
Manufacturers: Mylan Pharmaceuticals Inc., a Viatris Company
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Travoprost, Ophthalmic Solution, 0.004%, 2.5 mL (NDC 0378-9651-32) | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 07/07/2026 Updated 07/07/2026 Discontinued 07/07/2026 |
| Travoprost, Ophthalmic Solution, 0.004%, 5 mL (NDC 0378-9651-50) | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 07/07/2026 Updated 07/07/2026 Discontinued 07/07/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)